Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2867
  • Joined

  • Last visited

Everything posted by Harrison Stafford

  1. Every fan who thinks Kansas City has received special treatment this season should chip in and help him pay that fine.
  2. And that’s what the NFL wants.
  3. We survived the first quarter. Everyone take a deep breath.
  4. The Texans need to get off to a decent start and let ‘er rip. No one expects us to win this game, so we’ve got nothing to lose. Fake punts, double reverse passes….throw everything in the playbook at ‘em. LFG!
  5. When ImmunityBio’s, Anktiva, becomes the mainstay treatment for every kind of cancer, their CEO, Patrick Soon-Shiong, wins the Nobel Prize for Medicine, and I have enough money to buy all you heathens new cars, this will all seem like a dream……albeit, a bad dream at the moment. 27,800 shares with a cost basis of $9.77.
  6. ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances Published: Jan. 16, 2025 at 12:36 p.m. ET By Owen Tucker-Smith ImmunityBio shares rose after the company said it planned to submit multiple treatments for FDA commercial approval in 2025. Shares of the San Diego-based biotechnology company were recently up 16% to $2.77. The stock is down more than 57% over the last six months, and more than 28% over the last year. The company said Wednesday evening that it would submit a supplemental biologics license application, or BLA, for a treatment that targets a type of bladder cancer. BLAs, if approved by the FDA, allow companies to sell their products across state lines. The company said it would submit another BLA in 2025 for a treatment of patients with a certain type of lung cancer. The company said that a Phase 2b study had indicated positive results for patients for whom first and second treatment attempts have been unsuccessful when they used the company's Anktiva drug in combination with other inhibitors. Executive Chairman Patrick Soon-Shiong characterized improved outcomes for these types of lung cancer as an "unmet need." Soon-Shiong also owns the Los Angeles Times. ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of BCG in collaboration with the Serum Institute of India, and noted that there is currently a shortage of the drug IBRX +.65 to $3.04.
  7. Lol. Unfortunately, I’m so underwater in some of my other positions that I have a ways to go before I’m back in black. Hope springs eternal.
  8. EOSE + 1.12 to $6.33. Another 52 wk high. Holding 20,000 shares at avg cost of $1.98.
  9. I may be in the minority, but I’m pulling for you ying yangs vs ND.
  10. What is remarkable is the Texans didn’t collapse after this play turning the momentum right around with the blocked extra point and the two point conversion.
  11. Turn out the lights The party’s over
  12. I am not believing this.
  13. This team continues to make stupid mistakes. Looking at you DeMeco.
  14. Well, it’s only 6-0. Could be worse. Having said that, I have no faith in this team to advance today.
  15. They just arrived at their hotel in Arlington. Said the drive was awful because of the constant rain, but the roads were clear.
  16. Daughter and son-in-law are on the way taking the same route you took. Appreciated your updates and have passed them on.
  17. Bought 1000/sh IRBT at 12.738 and sold 5 March 17 at 1.20.
  18. Today, RGTI is $19 and IRBT is +2.91 to $12.82. Not chasing RGTI, but Amazon was going to pay $61/sh for IRBT before the government intervened and stopped the deal. Don’t think it’s going back to the 60s anytime soon, but there’s a lot of room between the current share price and 60.
  19. Theirs is a franchise that will always be looking back because that’s all they’ve got.
  20. Mobile QB’s give us issues. Will Howard is not mobile and stands in the pocket. Time to tee off.
  21. EOSE +.81 to $5.67. Another 52 wk high.
×
×
  • Create New...